Novel Injection Methods

Aetna covers suprachoroidal injection of triamcinolone acetonide injectable suspension (Xipere) for macular edema associated with uveitis when CPB 1000 selection criteria are met and covers subretinal rtPA for sub-macular hemorrhage, but considers suprachoroidal delivery of other drugs and the Mercator Bullfrog micro‑infusion device experimental/investigational and not covered. CPT/HCPCS limits: 67516 is covered only for Xipere per criteria (67516 and 0699T are not covered for other suprachoroidal agents), C9759 is not covered for Bullfrog use, and no specific HCPCS codes are assigned for subretinal rtPA in this CPB.

"The Mercator Bullfrog micro-infusion device is considered experimental and investigational for direct adventitial delivery of diagnostic or therapeutic agents via blood vessel walls because there i..."

Sign up to see full coverage criteria, indications, and limitations.